When buyers search for a pharmaceutical cleanroom HVAC solution, they are rarely looking for “cooling” alone. They are trying to answer a more important question: Can this DX system support the required cleanroom class, filtration strategy, pressure cascade, and temperature/humidity stability without creating GMP risk?
That is the real decision point.
For pharmaceutical projects in Southeast Asia, South Asia, and other manufacturing-heavy markets, DX-based systems can be a practical option for many support and controlled production spaces. But they should not be specified like ordinary commercial air conditioning. In pharma, the discussion must start with room function, contamination risk, cleanliness class, and environmental stability—not just cooling capacity.
One of the biggest mistakes in pharmaceutical HVAC selection is assuming that GMP gives one fixed parameter table for every cleanroom. It does not.
ISO 14644 classifies cleanrooms by airborne particle concentration. FDA also makes clear that manufacturers should not rely on ISO 14644 alone when qualifying a pharmaceutical aseptic facility; ISO standards need to be used together with FDA regulations, guidance, and other relevant references.
WHO likewise states that temperature, relative humidity, and ventilation should be appropriate for the product, process, equipment, and personnel, and EU GMP Annex 1 says temperature and RH should be controlled within ranges that support product, process, personnel, and the required cleanliness level.
That means the right way to write this topic is not “mandatory GMP values for ISO 5–8,” but rather: typical engineering design targets used to support ISO 5–8 pharmaceutical spaces under GMP practice. That distinction matters. It protects your credibility with engineers and QA-minded buyers.
FDA states that airflow sufficient to achieve at least 20 air changes per hour is typically acceptable for ISO 8 support rooms. Practical control target: ±2 °C and ±5% RH.
A common engineering target is 30–65 ACH, although some pharmaceutical ISO 7 designs run higher depending on personnel load and process sensitivity. Treat as a design exercise, not a copy-paste rule.
At this level, buyers evaluate whether the system can maintain stable airflow, support terminal filtration, recover quickly after disturbance, and hold temperature/RH within a tighter envelope.
EU GMP Annex 1 emphasizes first air protection and unidirectional airflow. The better engineering language is UDAF / first-air protection, not “just ACH.” ULPA is not a universal GMP requirement for ISO 5.
In cleanroom projects, “Do you use HEPA or ULPA?” is often the wrong first question. The better questions focus on room classification, process risk, filtration strategy, and system integration.
Under EN 1822 / ISO 29463 practice, H13 and H14 are HEPA classes, while U15 to U17 are ULPA. Both are used in critical clean-air applications, but ULPA brings higher pressure-drop implications and should be selected only where the application really justifies it.
HEPA is the mainstream terminal filtration choice; ULPA is a special-choice option, not a default requirement. Choose the filtration level because the process and airflow design justify it—not because “higher is always better.”
DX systems can be an excellent fit for many pharmaceutical spaces when properly specified. But they require more caution in highly critical zones where validation, recovery time, and airflow visualization are especially important.
That is exactly why the supplier’s engineering judgment matters. A seller who treats every pharmaceutical room as “cooling + HEPA” is not reducing risk for the buyer.
Songxin’s DX portfolio aligns with the realities of pharmaceutical and clean-environment HVAC selection — covering precision control, ducted airflow, dehumidification-heavy operation, and packaged support-space solutions.
Documented with ±1 °C temperature control, ±5% RH humidity control, integrated PTC electric reheating + electrode humidification. Suitable for laboratories, pharmaceutical workshops, and high-requirement spaces.
200–300 Pa external static pressure, flexible indoor/outdoor split arrangement, BMS access, and an installation format that fits mid-to-long duct runs for terminal filtration coordination.
24.5–116.2 kW cooling capacity, 15–75 kg/h dehumidification, 4,500–20,000 m³/h airflow, and a dual-system design described as improving temperature and humidity control precision.
Packaged format with 35–180 kW cooling, 200–450 Pa ESP, integrated fresh air + G3 pre-filtration sections, and microprocessor control. Practical for less critical production support and logistics-adjacent zones.
If the project is pharma or cleanroom-related, the most relevant starting points are usually the more controllable and integrable DX formats:
If an owner, distributor, or EPC contractor wants a useful quotation instead of a generic price list, they should provide:
That information lets the supplier answer the real question: Is a DX solution appropriate here, and if so, which type of DX solution?
The right DX unit for a pharmaceutical project is not simply the one with enough cooling capacity. It is the one that can support the required cleanroom class, filtration strategy, pressure cascade, and validated temperature/humidity stability — while still being practical to install, maintain, and quote in the real project environment.
GMP and ISO do not give one universal design table for every room, but they do make one thing very clear: environmental control has to match the risk of the process.
For many ISO 8 and ISO 7 pharmaceutical spaces, and for selected ISO 6 applications, DX systems can be the right answer when designed properly. For ISO 5 critical zones, the discussion must shift toward first air, unidirectional airflow, and contamination control — not just equipment tonnage.
And that is where supplier credibility matters most.
Send Songxin your room class, ACH target, temperature/RH requirement, and filtration plan. We can help you evaluate whether a DX solution is suitable and recommend the right configuration for your project.
